










# SLEIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

Iñigo Rua-Figueroa <sup>1</sup>, M Jesus García de Yébenes,<sup>2</sup> Julia Martínez-Barrio,<sup>3</sup> María Galindo Izquierdo,<sup>4</sup> Jaime Calvo Alén <sup>5</sup>, Antonio Fernández-Nebro <sup>6</sup>, Raúl Menor-Almagro,<sup>7</sup> Loreto Carmona <sup>8</sup>, Beatriz Tejera Segura,<sup>9</sup> Eva Tomero,<sup>10</sup> Mercedes Freire-González,<sup>11</sup> Clara Sangüesa,<sup>12</sup> Loreto Horcada,<sup>13</sup> Ricardo Blanco <sup>14</sup>, Esther Uriarte Itzazelaia,<sup>15</sup> Javier Narváez,<sup>16</sup> José Carlos Rosas Gómez de Salazar,<sup>17</sup> Silvia Gómez-Sabater,<sup>18</sup> Claudia Moriano Morales,<sup>19</sup> Jose L Andreu,<sup>20</sup> Vicente Torrente Segarra,<sup>21</sup> Elena Aurrecochea,<sup>22</sup> Ana Perez,<sup>23</sup> Javier Nóvoa Medina,<sup>24</sup> Eva Salgado,<sup>25</sup> Nuria Lozano-Rivas,<sup>26</sup> Carlos Montilla,<sup>27</sup> Esther Ruiz-Lucea,<sup>28</sup> Marta Arevalo,<sup>29</sup> Carlota Iñiguez,<sup>30</sup> María Jesús García-Villanueva,<sup>31</sup> Lorena Exposito,<sup>32</sup> Mónica Ibáñez-Barceló,<sup>33</sup> Gema Bonilla,<sup>34</sup> Irene Carrión-Barberà <sup>35</sup>, Celia Erasquin,<sup>1</sup> Jorge Juan Fragio Gil <sup>36</sup>, Angela Pecondón,<sup>37</sup> Francisco J Toyos,<sup>38</sup> Tatiana Cobo,<sup>39</sup> Alejandro Muñoz-Jiménez <sup>40</sup>, Jose Oller,<sup>41</sup> Joan M Nolla,<sup>42</sup> J M Pego-Reigosa <sup>43</sup>

**To cite:** Rua-Figueroa I, García de Yébenes MJ, Martínez-Barrio J, *et al*. SLEIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort. *Lupus Science & Medicine* 2024;**11**:e001096. doi:10.1136/lupus-2023-001096

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/lupus-2023-001096>).

Received 9 November 2023  
Accepted 22 March 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Iñigo Rua-Figueroa; iruafer@gobiernodecanarias.org

## ABSTRACT

**Objective** To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLEIS-R) and to validate it in a large multicentre lupus cohort.

**Methods** We used data from the prospective phase of RELESSER (RELESSER-PROS), the SLE register of the Spanish Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLEIS score, plus all other potential predictors identified in a literature review. Performance was analysed using the C-statistic and the area under the receiver operating characteristic curve (AUROC). Internal validation was carried out using a 100-sample bootstrapping procedure. ORs were transformed into score items, and the AUROC was used to determine performance.

**Results** A total of 1459 patients who had completed 1 year of follow-up were included in the development cohort (mean age, 49±13 years; 90% women). Twenty-five (1.7%) had experienced ≥1 severe infection. According to the adjusted multivariate model, severe infection could be predicted from four variables: age (years) ≥60, previous SLE-related hospitalisation, previous serious infection and glucocorticoid dose. A score was built from the best model, taking values from 0 to 17. The AUROC was 0.861 (0.777–0.946). The cut-off chosen was ≥6, which exhibited an accuracy of 85.9% and a positive likelihood ratio of 5.48.

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Severe infection is frequent in patients with systemic lupus erythematosus, and, while several risk factors have been identified, no clinically useful risk score has been developed to date.

## WHAT THIS STUDY ADDS

⇒ The authors developed and internally validated an accurate and feasible score for the prediction of serious infection in clinical practice.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The score could help clinicians to make informed decisions on the use of immunosuppressants and the implementation of preventive measures.

**Conclusions** SLEIS-R is an accurate and feasible instrument for predicting infections in patients with SLE. SLEIS-R could help to make informed decisions on the use of immunosuppressants and the implementation of preventive measures.

## INTRODUCTION

Patients with systemic lupus erythematosus (SLE) are at increased risk of severe infections

that vary with the severity of the disease, use of immunosuppressants (including glucocorticoids), comorbidities and organ damage.<sup>1–7</sup> Moreover, infection remains a leading contributor to mortality in patients with SLE.<sup>5,8–10</sup>

Properly estimating the risk of infection in patients with SLE is paramount if we are to balance immunosuppression and implement preventive measures. Unfortunately, very few predictive models of severe infection in patients with SLE have been published to date. One systematic literature review showed that most of those published were from retrospective cohorts and were subjected to methodological limitations and a high risk of bias.<sup>11</sup> No evidence-based, widely validated, and suitable score for predicting severe infection in patients with SLE has been developed for use in daily clinical practice. Conversely, scores for predicting major infection have been successfully developed for other systemic immune-mediated rheumatic diseases, such as rheumatoid arthritis.<sup>12</sup>

Our group attempted to develop a tool for the prediction of severe infections in SLE. The SLE Severe Infection Score (SLESIS) was developed using data gathered from the retrospective cross-sectional phase of the Spanish Rheumatology Society Systemic Lupus Erythematosus Registry (RELESSER-TRANS)<sup>13</sup> and validated in an external cohort, the University College London Hospital SLE cohort, which was also based on retrospective-longitudinal data. The original SLESIS incorporated seven predictors, including the Katz severity index (KSI).<sup>14</sup> However, the performance of SLESIS was only moderate, with an area under the receiver operating characteristic curve (AUROC) of 0.63 (95% CI 0.56 to 0.70) at diagnosis and of 0.79 (95% CI 0.73 to 0.85) at the time of infection.

In the current study, we aimed to improve the ability of SLESIS to predict the risk of infection by reformulating the constituent variables and adding new markers, if appropriate, based on higher quality data from the prospective phase of the RELESSER register (namely, RELESSER-PROS). We also wished to improve the feasibility of our index by avoiding, if possible, inclusion of the KSI, which is cumbersome to calculate and has a limited degree of validation. Furthermore, we performed an internal validation of the resulting index.

## PATIENTS AND METHODS

### Design and participants

The data for this study were gathered from the RELESSER-PROS register, a multicentre prospective cohort of patients with SLE involving 39 Spanish hospitals. The RELESSER cohort comprises patients who meet  $\geq 4$  American College of Rheumatology (ACR) classification criteria for SLE, are under active follow-up, and have been recruited from the cross-sectional stage of the register (RELESSER-TRANS). Only patients with sufficient information regarding serious infection were included in the analysis. The general characteristics of the RELESSER register have been reported elsewhere.<sup>15</sup> The baseline

visits of RELESSER-PROS took place between 2014 and 2023, and the patients are under active yearly follow-up.

### Data collection and variable definitions

Potential predictors were extracted from data collected at the baseline visit (visit 1) and comprise demographic data and clinical characteristics, disease activity (Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Activity Index (SELENA-SLEDAI)) at baseline, severity (KSI), organ damage (Systemic Lupus International Collaborating Clinics (SLICC)-ACR/Damage Index) (SDI), comorbidities (Charlson comorbidity index), previous hospital admission for SLE, previous serious infections (any time after diagnosis of SLE), laboratory data (serum creatinine, lymphopenia  $<1000/\text{mm}^3$ , hypocomplementemia) and treatments received (antimalarials, immunosuppressants, rituximab, glucocorticoids and prednisone dose (or equivalent) (ie, dose at visit 1, and maximum prednisone dose during the observation period). In order to avoid overfitting of the model, which would have led to performance overestimation, an effort was made to reduce the number of candidate predictors based on our previous studies and a thorough review of the literature.

The dependent variable was the occurrence of a serious infection (ie, one leading to hospitalisation or death) during the first year of follow-up.

### Statistical analysis

Descriptive data were expressed as measures of central tendency and dispersion in the case of quantitative variables and as frequency tables and percentages in the case of qualitative variables. A total of 362 out of 1821 patients were excluded owing to missing data regarding serious infection. A bivariate analysis comparing included patients ('valid case') and excluded patients was carried out. Although the excluded group was characterised by a higher Charlson index, lower percentage of antimalarials and more frequent use of mycophenolate, the percentages for previous infection differed significantly between the groups (99 (5.5%) vs 11 (3.1%),  $p=0.027$ ), with the analysis favouring the 'valid' group (ie, more previous infection in the 'valid' group) (see online supplemental table 1 for the complete set of results).

A baseline comparison of patients in terms of severe infection during the first year of follow-up was performed using the  $t$  test or the Mann-Whitney test (continuous data) and the  $\chi^2$  test with a Fisher exact test (categorical data).

Bivariate logistic regression was used to analyse the predictive effect of baseline variables on the development of severe infection in the first year of follow-up. A predictive model was built based on multivariate logistic regression models and included all the predictors reaching a  $p$  value  $<0.25$  in the bivariate analysis (saturated model), with successive elimination of variables without discriminatory power. When multiple options were available for adjustment (eg, adjust for proportion

with any glucocorticoid or proportion with a glucocorticoid dosage threshold), we based our decisions on exploratory regression analyses. The most parsimonious model with the lowest Akaike and Bayesian information criteria (AIC and BIC) values was chosen as the final model. The performance of the final model was evaluated based on discrimination and calibration parameters.

In order to seek a more realistic estimate of performance, the model was internally validated using bootstrapping techniques, which were based on all the data used in the development of the model and enabled more robust equations to be obtained. The *Transparent Reporting of multivariable prediction model for Individual Prognosis of Diagnosis*<sup>16</sup> statement was followed for this publication (see online supplemental material).

Each predictor in the final adjusted model was transformed into a specific score item based on its corresponding logistic regression coefficient. The OR of each predictor was rounded up to the nearest integer for simplification. The sum of these values yielded the Systemic Lupus Erythematosus Severe Infection Score-Revised (SLESIS-R), whose performance was calculated using the AUROC. Finally, the cut-off point with the best validity parameters (sensitivity, specificity, likelihood ratio) was chosen.

The analysis was performed using STATA V.18 (STATA V.2023, Stata Statistical Software, Release V.18.0. College Station, Texas: Stata Corp LLC).

## RESULTS

A total of 1459 patients who had completed visit 2 (1 year of follow-up) or had had infections or died during the study period were included in the analysis. The mean ( $\pm$ SD) age was  $49\pm 13$  years, 90% of patients were women and 94% were Caucasian. The mean disease duration was  $14.2\pm 8.8$  years.

The clinical characteristics, laboratory findings, comorbidities and treatments are shown in [table 1](#). At baseline, the mean SLEDAI was low ( $2.7\pm 3.8$ ).

The frequency of cancer and diabetes was low in both cases and controls ([table 1](#)).

Up to 6% had had a prior major infection, that is, before entering the study, and 25% had been hospitalised with SLE. Twenty-five (1.7%) had experienced at least one serious infection in the first year of follow-up. A total of 13 patients (0.91%) died, 2 due to serious infection. Nine patients (0.49%) were admitted to the ICU; in 2 cases, admission was because of infection.

The results of the univariate analysis are shown in [table 2](#). Patients with infection were older (OR=1.04;  $p=0.006$ ), with more damage accrual (OR=1.29;  $p<0.0001$ ) and comorbidity (OR=1.34;  $p<0.0001$ ), including a higher frequency of chronic kidney disease (OR=3.82;  $p=0.004$ ). The predictors that most increased the probability of serious infection in the following year were previous serious infection (OR=14.78;  $p<0.0001$ ), previous hospitalisation (OR=15.50;  $p<0.0001$ ) and cyclophosphamide

(OR=12.38;  $p<0.002$ ) or glucocorticoid dose  $\geq 30$  mg/day (OR=7.47;  $p=0.004$ ) ([table 2](#)).

## Predictive model building

The potential predictors with  $p\leq 0.25$  that were entered into the multivariate logistic regression model were age, Charlson comorbidity index, chronic kidney disease, SDI, KSI, SLE-related hospitalisation, previous serious infection, treatments such as antimalarials, cyclophosphamide, mycophenolate as well as the maximum dose of glucocorticoids used during the observation period of  $\geq 30$  mg prednisone/day (or equivalent). In order to simplify construction of the index, we made the variable age dichotomous, namely,  $<60$  years or  $\geq 60$  years.

Starting from a saturated model (all predictors with a bivariate  $p$  value of  $p\leq 0.250$ ), we selectively eliminated variables without discriminatory power. A parallel stepwise procedure revealed no differences with the successive elimination approach. Eventually, the most parsimonious model, that is, that with the lowest AIC and BIC values, was chosen. According to our final adjusted multivariate model, the occurrence of a serious infection in the following year in SLE can be predicted from four variables: age  $\geq 60$  years ( $\beta=1.80$ ; OR=6.06;  $p=0.002$ ), previous admission for SLE ( $\beta=1.92$ ; OR=6.84;  $p=0.007$ ), previous infection ( $\beta=1.81$ ; OR=6.09;  $p=0.002$ ) and having received a maximum dose of glucocorticoids  $\geq 30$  mg ( $\beta=2.19$ ; OR=8.93;  $p=0.010$ ) ([table 3](#)). The KSI was eventually excluded from the model. Our model exhibited adequate performance, with 97.8% correct classification. The discrimination parameters revealed an AUROC of 0.874 (0.777–0.974), with adequate calibration (Hosmer-Lemeshow,  $p=0.932$ ).

## Internal validation

The model was internally validated using a bootstrapping procedure, taking up to 100 samples with replacement and adjustment for overfitting of the model using a heuristic shrinkage factor. The ORs and  $\beta$ -coefficients of the adjusted model are provided in the online supplemental table 2. This model revealed appropriate discrimination parameters, with a C statistic of 0.810 (0.715–0.893).

The robustness of each predictor, measured as the number of times that it is included in the 100 bootstrap samples, is displayed in the online supplemental table 3.

## SLESIS-R index design

Up to 11 mathematical transformations of the final model were performed to create the index; of these, 6 were based on coefficients and 5 on the ORs of the model adjusted for overfitting (online supplemental table 4). This approach yielded 11 possible indices (online supplemental tables 5 and 6). No significant differences were observed between the 11 ROC curves obtained with these indices (online supplemental figure 1). Consequently, the OR-based transformation (avoiding the effect of the constant) with the

**Table 1** Sample description and group comparisons

Potential predictors	Total	Serious infection		P value*
	N=1459	Absent N=1434	Present N=25	
Sociodemographic variables				
Age (visit 1)	49.1±13.5	48.9±13.3	56.6±18.2	<b>0.030</b>
Female sex	1315 (90.4%)	1292 (90.4%)	23 (92.0%)	1.000
Ethnicity				
Caucasian	1327 (93.8%)	1304 (93.9%)	23 (92.0%)	0.407
Latin-American	64 (4.5%)	63 (4.5%)	1 (4.0%)	
Other	23 (1.6%)	22 (1.6%)	1 (4.0%)	
Smoking				
Never	652 (48.9%)	641 (49.0%)	11 (45.8%)	0.065
Ever or current smoker	680 (51.1%)	667 (51.0%)	13 (54.2%)	
Clinical features and comorbidities				
Charlson comorbidity index	2.5±1.8	2.5±1.8	3.9±2.7	<b>0.004</b>
Diabetes	50 (3.5%)	48 (3.4%)	2 (8.3%)	0.200
Malignancy	40 (2.8%)	39 (2.7%)	1 (4.2%)	0.493
Chronic kidney disease	148 (10.6%)	141 (10.3%)	7 (30.4%)	<b>0.002</b>
SLE activity (SLEDAI)	2.7±3.8	2.7±3.8	3.2±5.7	0.918
Damage (SDI)	1.4±1.8	1.4±1.8	2.8±2.2	0.0005
Katz severity index	4.4±2.0	4.4±1.9	5.7±1.8	<b>0.0004</b>
SLE-related hospitalisation	354 (25.4%)	334 (24.4%)	20 (83.3%)	<b>&lt;0.0001</b>
Previous serious infection	88 (6.1%)	77 (5.4%)	11 (45.8%)	<b>&lt;0.0001</b>
Laboratory results				
Creatinine	1.03±1.82	1.03±1.83	1.15±0.71	0.468
Lymphopenia (<1000/mm <sup>3</sup> )	272 (18.8%)	266 (18.7%)	6 (25.0%)	0.436
Hypocomplementemia	540 (37.5%)	531 (37.5%)	9 (37.5%)	1.000
Treatments				
Maximum GC dose				<b>0.044</b>
≤5 mg	526 (67.1%)	518 (67.6%)	8 (44.4%)	
>5 mg and<10 mg	116 (14.8%)	112 (14.6%)	4 (22.2%)	
≥10 mg and<30 mg	100 (12.8%)	97 (12.7%)	3 (16.7%)	
≥30 mg	29 (3.7%)	26 (3.4%)	3 (16.7%)	
Methylprednisolone pulse	13 (1.7%)	13 (1.7%)	–	
Antimalarials	802 (55.0%)	791 (55.2%)	11 (44.0%)	0.266
Cyclophosphamide	12 (0.8%)	10 (0.7%)	2 (8.0%)	<b>0.017</b>
Mycophenolate	114 (7.8%)	109 (7.6%)	5 (20.0%)	<b>0.022</b>
Rituximab	45 (3.1%)	44 (3.1%)	1 (4.0%)	0.546
Other (MTX or azathioprine)	215 (14.7%)	212 (14.8%)	3 (12.0%)	1.000

\*P values for absent versus present comparisons. Statistically significant variables are highlighted in bold.

GC, glucocorticoid; MTX, methotrexate; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; SLE, systemic lupus erythematosus; SLEDAI, SLE Activity Index.

best performance (higher AUROC), corresponding to number nine and consisting of rounding the OR of each predictor, was finally chosen.

The final SLESIS-R is shown in [table 4](#). The score is based on values ranging from 0 to 17. The ROC curve

of the SLESIS-R is displayed in [figure 1](#). The resulting AUROC was 0.861 (0.777–0.946). The validity parameters are displayed in [table 5](#). According to these parameters, a score ≥6 was chosen as the best cut-off point, exhibiting a sensitivity of 76% and specificity of



**Table 2** Univariate analysis

Potential predictors	OR (95%CI)	P value
Age	1.04 (1.01 to 1.07)	<b>0.006</b>
Female	1.22 (0.28 to 5.23)	0.789
Latin American origin	0.90 (0.12 to 6.77)	0.918
Current smoking	1.45 (0.56 to 3.78)	0.446
Charlson comorbidity index	1.34 (1.15 to 1.56)	<b>&lt;0.0001</b>
Diabetes	0.33 (0.53 to 6.44)	0.333
Malignancy	1.28 (0.21 to 7.67)	0.788
Chronic kidney disease	3.82 (1.54 to 9.44)	<b>0.004</b>
Disease activity (SELENA-SLEDAI)	1.03 (0.94 to 1.13)	0.559
Organ damage (SDI)	1.29 (1.13 to 1.48)	<b>&lt;0.0001</b>
Katz severity index	1.33 (1.12 to 1.58)	<b>0.001</b>
SLE-related hospitalisation	15.50 (5.26 to 45.69)	<b>&lt;0.0001</b>
Previous serious infection	14.78 (6.41 to 34.1)	<b>&lt;0.0001</b>
Creatinine	1.02 (0.88 to 1.19)	0.756
Lymphopenia (any time)	1.45 (0.57 to 3.68)	0.439
Hypocomplementemia	1.00 (0.43 to 2.30)	1.000
Maximum GC dose over the period (prednisone)	–	–
≤5 mg	1	NA
>5 mg and<10 mg	2.31 (0.68 to 7.81)	0.177
≥10 mg and<30 mg	2.00 (0.52 to 7.68)	0.311
≥30 mg	7.47 (1.87 to 29.82)	<b>0.004</b>
Antimalarials	0.64 (0.29 to 1.42)	0.270
Cyclophosphamide	12.38 (2.57 to 59.70)	<b>0.002</b>
Mycophenolate	3.04 (1.12 to 8.25)	<b>0.029</b>
Rituximab	1.32 (0.17 to 9.95)	0.790
Methotrexate or azathioprine	0.79 (0.23 to 2.65)	0.698

Variables associated with serious infection.  
Statistically significant variables are highlighted in bold.  
GC, glucocorticoid; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Activity Index; SLE, systemic lupus erythematosus.

**Table 3** Adjusted final multivariate predictive model

Predictor	OR (95%CI)	P value
Age	1.03 (1.00 to 1.06)	0.040
Previous SLE-related hospitalisation	3.81 (1.33 to 10.97)	0.013
Previous serious infection	3.72 (1.58 to 8.77)	0.003
Having received a GC dose≥30 mg/d	4.45 (1.34 to 14.76)	0.015

GC, glucocorticoid; SLE, systemic lupus erythematosus.

**Table 4** SLESIS-R index calculator

Predictor	Score
Age (years)≥60	4
Previous SLE-related hospitalisation	4
Previous serious infection	4
GC doses	
>5 mg and<10 mg	2
≥10 mg and<30 mg	2
≥30 mg	5

GC, glucocorticoids; SLE, systemic lupus erythematosus; SLESIS-R, Systemic Lupus Erythematosus Infection Score-Revised.


86.6%, with an accuracy of 85.9% and positive likelihood ratio of 5.48.

## DISCUSSION

Based on data from a large, prospective multicentre cohort, we developed and internally validated an improved version of SLESIS, namely SLESIS-R, a score that is able to predict the risk of severe infection in patients with SLE during the following year. The performance of SLESIS-R was very favourable, notably improving on the previous version of the score in terms of the AUROC (0.861 (95% CI 0.777 to 0.946) vs 0.790 (95% CI 0.730 to 0.850)). The SLESIS-R also improved feasibility, given the greater simplicity of the new version and the exclusion of the KSI. This latest version includes only four clinical parameters, namely, age, previous SLE-related hospitalisation, previous severe infection and glucocorticoid dose ≥30 mg/day, all of which are readily available in the patient's clinical records. The four parameters found are consistent with most previous studies regarding major infection-associated factors, which identify mostly age, glucocorticoid dose and previous serious infection as the best predictors of severe infection in SLE.<sup>12 4 6 7 11 17</sup>

In addition, the prospective nature of the data used to develop SLESIS-R, with a better-defined temporal framework, increases the reliability of the results.

Because of its simplicity and the fact that it is based on clinical parameters and not laboratory results, SLESIS-R could become a useful instrument for predicting infection in both daily clinical practice and observational studies and even in clinical trials in Caucasians. In fact, the use of numerical probabilities is to be preferred not only for decision-making but also in teaching materials and in communication between physicians.<sup>18</sup> We think that our score improves prediction of the risk of infection, facilitating an informed decision-making process and supporting more careful implementation of preventive measures. Thus, in the case of a patient with an increased risk of serious infection, namely, a SLESIS-R score >6, this information should be considered when selecting therapy and for overall patient management (ie, taking



**Figure 1** ROC curve for the SLESIS-R index. ROC, receiver operating characteristic curve; SLE, systemic lupus erythematosus; SLESIS-R, SLE Severe Infection Score-Revised.

extreme precautions to avoid serious infections, such as vaccinations, hygiene, smoking cessation, etc). Similarly, seeking early medical care in the case of fever would also be appropriate. Additionally, we should perhaps choose therapies with a reduced risk of infection or opt for more aggressive' tapering of glucocorticoids.

Several previous studies have attempted to develop predictive models of infection in patients with SLE. All of

them are discussed below and were based, in contrast to our study, on retrospective data analysis (with the exception of Torres-Ruiz *et al*<sup>19</sup>) and single-centre SLE cohorts.

The first formal attempt to develop a predictive model and rigorously test its performance was that of Yuhara *et al*,<sup>17</sup> which was carried out in an Asian single-centre cohort. In contrast to SLESIS, the model of Yuhara *et al* was developed for inpatients

**Table 5** SLESIS-R—validity parameters

Cut-off point	Sensitivity	Specificity	Properly classified	Likelihood ratio
≥ 0	100%	–	1.71%	1.00
≥ 2	92.0%	51.0%	51.7%	1.88
≥ 4	88.0%	59.3%	59.8%	2.16
≥ 5	76.0%	85.1%	84.9%	5.09
<b>≥ 6</b>	<b>76.0%</b>	<b>86.1%</b>	<b>85.9%</b>	<b>5.48</b>
≥ 8	72.0%	90.7%	90.4%	7.76
≥ 9	44.0%	96.7%	95.8%	13.42
≥ 10	40.0%	97.3%	96.4%	15.09
≥ 12	20.0%	99.1%	97.7%	22.06
≥ 13	8.0%	99.9%	98.3%	57.36
≥ 17	4.0%	100%	98.4%	
>17	–	100%	98.3%	

The optimal cut-off point is highlighted in bold.  
SLESIS-R, Systemic Lupus Erythematosus Severe Infection Score-Revised.

with SLE. The independent predictors of infection, all of which were available at admission, were decreased serum albumin, increased serum creatinine and prednisolone  $\geq 60$  mg/day without methylprednisolone pulse therapy. Internal validation of the model yielded a valuable AUROC for cross-validation (0.846, CI not provided). However, it is difficult to generalise these results to an SLE outpatient population.

Torres-Ruiz *et al*<sup>19</sup> built a predictive score based on prospective clinical data and immunological-laboratory tests, the 'systemic lupus erythematosus infection predictive index'. The performance of the models, measured as the AUROC, was at most 0.75 (95% CI 0.56 to 0.85). However, a very low number of patients with SLE (ie, a total of 55 cases) were included in that study, and only 26% of the recorded infections were serious. Additionally, several of the immunological tests proposed are not widely available or standardised, thus limiting the feasibility of the index.

Restrepo-Escobar *et al*<sup>20</sup> developed a model for predicting bacterial infection in Latin-American patients with SLE, although, again, this model was limited to nosocomial infections and was, therefore, unable to predict serious infection in outpatients with more stable disease in terms of activity. Furthermore, no score was derived from the data obtained in the analysis.

Finally, Wang *et al*<sup>21</sup> conducted a study to evaluate the risk of major infection in an Asian SLE cohort and developed a prediction model that incorporated the following variables: SLEDAI  $>10$ , lymphocyte count  $<0.8 \times 10^9$  /L and serum creatinine  $>104$   $\mu\text{mol/L}$ . The authors identified patients at low risk of major infection (3%–5%) and patients at high risk of major infection (37%–39%) within the first 4 months in newly diagnosed SLE. Up to 69 infections were recorded in 494 patients (14%) in the first year of the disease, an incidence that is substantially higher than in our cohort. That discrepancy could be explained by ethnic differences (Caucasian vs Asian population) or by selection bias. Moreover, and in contrast to our design, the cohort studied by Wang *et al* was an inception cohort, with a higher level of baseline activity. This predictive model has not been validated to date.

Our study is subject to a series of limitations. First, the number of major infections was relatively low in the cohort, thus potentially compromising the stability of the models. Moreover, the patients included were predominantly Caucasian. Furthermore, given the low grade of disease activity in the cohort, the risk of infection associated with disease activity could be underestimated. Consequently, a more extensive and external validation process is required in order to test the performance of the SLESIS-R in external cohorts, ideally with a more severely ill patients, a higher number of serious infections and more ethnic diversity.

## CONCLUSIONS

1. SLESIS-R is an accurate instrument for predicting serious infections SLE and proved feasible for daily clinical practice.
2. SLESIS-R is simple and easy to calculate. It could help clinicians to make informed decisions on the use of immunosuppressive or biological therapy in patients with SLE and, therefore, to implement preventive measures.

### Author affiliations

<sup>1</sup>Department of Rheumatology, Hospital Universitario Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain

<sup>2</sup>Institute for Musculoskeletal Health, Madrid, Spain

<sup>3</sup>Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

<sup>4</sup>Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain

<sup>5</sup>Department of Rheumatology, Hospital Sierrallana, Vitoria, Spain

<sup>6</sup>UGC de Reumatología, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain

<sup>7</sup>Department of Rheumatology, Jerez Hospital, Jerez, Spain

<sup>8</sup>Instituto de Salud Musculoesquelética (INMUSC), Madrid, Spain

<sup>9</sup>Department of Rheumatology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain

<sup>10</sup>Department of Rheumatology, Hospital Universitario de la Princesa, Instituto de Investigación La Princesa, Madrid, Spain

<sup>11</sup>Department of Rheumatology, University Hospital Complex of A Coruña, A Coruña, Spain

<sup>12</sup>Department of Rheumatology, Hospital Germán Trias i Pujol, Barcelona, Spain

<sup>13</sup>Department of Rheumatology, Hospital de Navarra, Pamplona, Spain

<sup>14</sup>Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

<sup>15</sup>Donostia Ospitalea, San Sebastian, Spain

<sup>16</sup>Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain

<sup>17</sup>Department of Rheumatology, Marina Baixa Hospital, Alicante, Spain

<sup>18</sup>Department of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain

<sup>19</sup>University Hospital Centre León, Leon, Spain

<sup>20</sup>Department of Rheumatology, Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, Spain

<sup>21</sup>Hospital de Sant Joan Despi Moisès Broggi, Sant Joan Despi, Spain

<sup>22</sup>Department of Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain

<sup>23</sup>Immune System Diseases and Oncology Service, University Hospital "Príncipe de Asturias", Alcala de Henares, Spain

<sup>24</sup>Department of Rheumatology, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas GC, Spain

<sup>25</sup>Department of Rheumatology, Complejo Hospitalario de Orense, Ourense, Spain

<sup>26</sup>Department of Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain

<sup>27</sup>Department of Rheumatology, Hospital Clínico Universitario Salamanca, Salamanca, Spain

<sup>28</sup>Basurto University Hospital, Bilbao, Spain

<sup>29</sup>Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain

<sup>30</sup>University Hospital Lucus Augusti, Lugo, Spain

<sup>31</sup>Hospital Universitario Ramon y Cajal, Madrid, Spain

<sup>32</sup>Hospital Universitario de Canarias, La Laguna, Spain

<sup>33</sup>Department of Rheumatology, Son Llatzer Hospital, Mallorca, Spain

<sup>34</sup>Department of Rheumatology, La Paz University Hospital, Madrid, Spain

<sup>35</sup>Department of Rheumatology, Hospital del Mar, Barcelona, Spain

<sup>36</sup>La Fe University and Polytechnic Hospital, Valencia, Spain

<sup>37</sup>Miguel Servet University Hospital, Zaragoza, Spain

<sup>38</sup>Department of Rheumatology, Hospital Virgen Macarena, Sevilla, Spain

<sup>39</sup>Hospital Infanta Sofía, Madrid, Spain

<sup>40</sup>Hospital Universitario Virgen del Rocío, Sevilla, Spain

<sup>41</sup>Doctor Peset University Hospital, Valencia, Spain

<sup>42</sup>Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain

<sup>43</sup>Department of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain

X Iñigo Rúa-Figueroa @iruafer@gobiernodecanarias.org

**Acknowledgements** We are grateful to the RELESSER group collaborators for their invaluable contributions to register data collection. We also are grateful to the employees of the Spanish Rheumatology Society Research Unit for their commitment and professionalism. Finally, we are also grateful to SER for their review of the English translation of the manuscript.

**Contributors** All the authors have contributed in collecting data and reviewing the manuscript, being able to make intellectual contributions in all phases of research development, that is design, statistical analysis and discussion. Guarantor author: IR-F

**Funding** The authors declare that financial support for this study was received from the Spanish Foundation of Rheumatology (2021 research grant to the main author). The RELESSER-PROS register received financial support from GSK.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by Ethics Committee of Las Palmas. CODE: 130082. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer-reviewed.

**Data availability statement** Data are available upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Iñigo Rúa-Figueroa <http://orcid.org/0000-0002-7894-1690>

Jaime Calvo Alén <http://orcid.org/0000-0001-9378-8412>

Antonio Fernandez-Nebro <http://orcid.org/0000-0002-2962-9844>

Loreto Carmona <http://orcid.org/0000-0002-4401-2551>

Ricardo Blanco <http://orcid.org/0000-0003-2344-2285>

Irene Carrión-Barberà <http://orcid.org/0000-0002-7118-3954>

Jorge Juan Frago Gil <http://orcid.org/0000-0003-3473-7927>

Alejandro Muñoz-Jiménez <http://orcid.org/0000-0001-8884-9225>

J M Pego-Reigosa <http://orcid.org/0000-0003-3461-3537>

#### REFERENCES

- Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, *et al*. Incidence, associated factors and clinical impact of severe infections in a large, Multicentric cohort of patients with systemic lupus erythematosus. *Semin Arthritis Rheum* 2017;47:38–45.
- Bougatf S, Ajili F, Sayhi S. Severe infections in patients with systemic lupus erythematosus from Tunisia: prevalence and risk factors. *Lupus* 2023;32:704–9.
- Ko T, Koelmeyer R, Li N, *et al*. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. *Semin Arthritis Rheum* 2022;57:S0049-0172(22)00150-0.
- Abe K, Ishikawa Y, Kita Y, *et al*. Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study. *Arthritis Res Ther* 2022;24:179.
- Tektonidou MG, Wang Z, Dasgupta A, *et al*. Burden of serious infections in adults with systemic lupus erythematosus: A national Population-Based study, 1996–2011. *Arthritis Care Res (Hoboken)* 2015;67:1078–85.
- Ruiz-Irastorza G, Olivares N, Ruiz-Arruzo I, *et al*. Predictors of major infections in systemic lupus erythematosus. *Arthritis Res Ther* 2009;11:R109.
- Feldman CH, Hiraki LT, Winkelmayer WC, *et al*. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. *Arthritis Rheumatol* 2015;67:1577–85.
- Rúa-Figueroa I, López-Longo FJ, Del Campo V, *et al*. Bacteremia in systemic lupus erythematosus in patients from a Spanish Registry: risk factors, clinical and Microbiological characteristics, and outcomes. *J Rheumatol* 2020;47:234–40.
- Teh CL, Wan SA, Ling GR. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. *Clin Rheumatol* 2018;37:2081–6.
- Yurkovich M, Vostretsova K, Chen W, *et al*. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a Metaanalysis of observational studies. *Arthritis Care Res (Hoboken)* 2014;66:608–16.
- Restrepo-Escobar M, Granda-Carvajal PA, Aguirre DC, *et al*. Predictive models of infection in patients with systemic lupus erythematosus: A systematic literature review. *Lupus* 2021;30:421–30.
- Strangfeld A, Eveslage M, Schneider M, *et al*. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient. *Ann Rheum Dis* 2011;70:1914–20.
- Tejera Segura B, Rúa-Figueroa I, Pego-Reigosa JM, *et al*. Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British cohort. *BMJ Open* 2019;9:e028697.
- Katz JD, Senegal J-L, Rivest C, *et al*. A simple severity of disease index for systemic lupus erythematosus. *Lupus* 1993;2:119–23.
- Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, *et al*. Grupo de Trabajo en Enfermedades Autoinmunes Sistémicas de la Sociedad Española de Reumatología (EAS-SER); Unidad de Investigación de la Sociedad Española de Reumatología (UI-SER). National Registry of patients with systemic lupus erythematosus of the Spanish society of rheumatology: objectives and methodology. *Reumatol Clin* 2014;10:17–24.
- Moons KGM, Altman DG, Reitsma JB, *et al*. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015;162:W1–73.
- Yuhara T, Takemura H, Akama T, *et al*. Predicting infection in hospitalized patients with systemic lupus erythematosus. *Intern Med* 1996;35:629–36.
- Timmermans D. The roles of experience and domain of expertise in using numerical and verbal probability terms in medical decisions. *Med Decis Making* 1994;14:146–56.
- Torres-Ruiz J, Mejía-Domínguez NR, Zentella-Dehesa A, *et al*. The systemic lupus erythematosus infection predictive index (LIPI): a clinical-immunological tool to predict infections in lupus patients. *Front Immunol* 2018;9:3144.
- Restrepo-Escobar M, Castaño-González P, Galvis-García M, *et al*. Development and internal validation of a clinical prediction model of the risk of Nosocomial bacterial infection in patients with systemic lupus erythematosus. *Revista Colombiana de Reumatología (English Edition)* 2021;28:95–103.
- Wang H, Zhou Y, Yu L, *et al*. Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study. *Lupus Sci Med* 2022;9:e000725.



## SUPPLEMENTARY MATERIAL

**Table 1(suppl):** Comparisons between valid cases and excluded ones, for the model's variables

Predictor	Total	Cases excluded	Cases valid	Valor p
• Age	49.1±13.8	49.0±15.8	49.1±13.4	0.568
• Charlson Index	2.56±1.89	2.79±2.00	2.50±1.86	0.013
• Organ damage (SLICC/ACR DI)	1.42±1.82	1.41±1.91	1.42±1.79	0,643
• Katz Severity Index	4.41±1,97	4.42±2.03	4.41±1.96	0.781
• Chronic Kidney Disease	167 (10.3%)	19 (8.4%)	148 (10.6%)	0.312
• Previous hospitalization	416 (25.6%)	62 (27.2%)	354 (25.4%)	0.564
• Previous serious infection	99 (5.5%)	11 (3.1%)	88 (6.1%)	0.027
• Prednisone (maximum doses)				
- ≤5 mg		-	526 (68.2%)	
- >5 mg and <10 mg		-	116 (15.0%)	
- ≥10 mg and <30 mg		-	100 (13.0%)	
- ≥30 mg		-	29 (3.8%)	
• Antimalarials	451 (24.8%)	72 (19.9%)	379 (26.0%)	0.017
• Cyclophosphamide	15 (0.8%)	3 (0.8%)	12 (0.8%)	1.000
• Mycophenolate	131 (7.2%)	17 (4.7%)	114 (7.8%)	0.041

<b>Table 2 (suppl): Model building and correction for overadjustment</b>			
<b>Potential predictors</b>	<b>OR (95%CI) [p value]</b>	<b>Coefficient (ln(OR))</b>	<b>Adjusted coefficient</b>
<b>Sociodemographics</b>			
• Age			
- <60 years	Reference	Reference	Reference
- ≥60 years	6.06 (1.91-19.3) [0.002]	1.80	1.30
<b>Clinical features</b>			
• Charlson comorbidity index			
• Chronic kidney disease			
• Damage (SLICC/ACR DI)			
• Severity (Katz Index)			
• Hospitalization due to SLE	6.84 (1.68-27.8) [0.007]	1.92	1.39
• Previous severe infection	6.09 (1.94-19.1) [0.002]	1.81	1.31
<b>Treatment</b>			
• Prednisone: (max. dosage)			
- ≤5 mg	Reference	Reference	Reference
- >5 mg and <10 mg	2.07 (0.49-8.73) [0.323]	0.73	0.53
- ≥10 mg and <30 mg	2.29 (0.51-10.3) [0.280]	0.83	0.60
- ≥30 mg	8.93 (1.69-47.1) [0.010]	2.19	1.58
• Antimalarials			
• Cyclophosphamide			
• Mycophenolate			
<b>Constant</b>	0.0017	-6.37	-5.40
<b>Performance of the model</b>			
% right classification	97.8%		
<b>Discrimination</b>			
• AUC	0.874 (0.774-0.974)		0.810
• C-Statistic			(0.715-0.893)
<b>Calibration</b>			
• Goodness-of-fit (Hosmer-Lemeshow)	p=0.932		
SLICC/ACR DI: SLICC/ACR Damage Index; SLE: systemic lupus erythematosus; max: maximum. AUC: area under the curve.			

<b>Table 3 (suppl): Predictor reliability</b>	
Predictors	Number of times selected * N (%)
Age (years) $\geq 60$	92 (92%)
Previous SLE-related hospitalization	67 (67%)
Previous serious infection	87 (87%)
GC dose (prednisone or equivalent)	
>5 mg and <10 mg	24 (24%)
$\geq 10$ mg and <30 mg	29 (29%)
$\geq 30$ mg	80 (80%)
Charlson comorbidity index	27 (27%)
Chronic kidney disease	17 (17%)
Damage (SDI)	29 (29%)
Severity (KSI)	57 (57%)
Antimalarials	15 (15%)
Cyclophosphamide	11 (11%)
Mycophenolate	32 (32%)
*Number of times selected in bootstrapping procedure/100 samples. SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; KSI: Katz Severity Index.	

**Table 4 (suppl):** Transformation of the coefficients and OR of the adjusted model

<b>Transformation</b>	<b>Mathematical formulation</b>
<i>Coefficient-based</i>	
Transformation 1	Eliminates the constant and multiplies the coefficient by 5 to increase the range of the scale
Transformation 2	Sum 1 to transformation 1 (avoiding the 0 value in reference categories)
Transformation 3	Eliminates the constant and divides by the lowest coefficient
Transformation 4	Sum 1 to transformation 3 (avoiding the 0 value in reference categories)
Transformation 5	Eliminates the constant and divides by the lowest coefficient and multiplies by 2
Transformation 6	Sum 1 to transformation 5 (avoiding the 0 value in reference categories)
<i>OR-based</i>	
Transformation 7	Divide OR by the lowest OR and round off the value
Transformation 8	Sum 1 to transformation 7 (avoiding the 0 value in reference categories)
Transformation 9	OR rounded
Transformation 10	Sum 1 to transformation 7 (avoiding the 0 value in reference categories)
Transformation 11	OR rounded with 0 in no significant categories of GC
OR: odds ratio. GC: Glucocorticoids	



**Table 5 (suppl):** Transformations based on the coefficients of the adjusted model

Predictors	$\beta$ adjusted	Transformations					
		1	2	3	4	5	6
• Age							
- <60 years	<b>0</b>	0	1	0	1	0	1
- $\geq$ 60 years	<b>1.30</b>	7	8	2	3	4	5
• Hospitalization due to SLE	<b>1.39</b>	7	8	3	4	6	7
• Previous infection	<b>1.31</b>	7	8	2	3	4	5
• Prednisone (max. dosage)	<b>0</b>	0	1	0	1	0	1
- $\leq$ 5 mg	<b>0.53</b>	3	4	1	2	2	3
- >5 mg y <10 mg	<b>0.60</b>	3	4	1	2	2	3
- $\geq$ 10 mg y <30 mg	<b>1.58</b>	8	9	3	4	6	7
- $\geq$ 30 mg							
• Constant	<b>-5.40</b>						
Scale range		<b>0-29</b>	<b>0-33</b>	<b>0-10</b>	<b>0-14</b>	<b>0-20</b>	<b>0-24</b>

SLE: Systemic lupus erythematosus. max: maximum.

**Table 6 (suppl):** Transformations based on the ORs of the adjusted model

Predictors	OR	Transformations				
		7	8	9	10	11
• Age						
- <60 years	<b>Ref</b>	0	1	0	1	0
- $\geq$ 60 years	<b>3.67</b>	2	3	4	5	4
• Hospitalization due to SLE	<b>4.01</b>	2	3	4	5	4
• Previous infection	<b>3.71</b>	2	3	4	5	4
• Prednisone (max. dosage)	<b>Ref</b>	0	1	0	1	0
- $\leq$ 5 mg	<b>1.70</b>	1	2	2	3	0
- >5 mg and <10 mg	<b>1.82</b>	1	2	2	3	0
- $\geq$ 10 mg and <30 mg	<b>4.85</b>	3	4	5	6	5
- $\geq$ 30 mg						
• Constant	<b>0.00</b>					
Scale range		<b>0-9</b>	<b>0-13</b>	<b>0-17</b>	<b>0-21</b>	<b>0-17</b>

max: maximum.

**Figure 1 (suppl):** ROC curves for the transformations of the OR and coefficients